Finally, further elucidation of potential Itpkb roles in Alzheimer’s disease (176, 177), multiple sclerosis (178), and malignant melanoma (179) might unveil additional therapeutic opportunities or liabilities for selective Itpkb inhibitors. Here, ITPKB is linked to melanoma.